// STATE LEGISLATION TRACKER

Washington SB 6182: Providing prescription drug coverage for the treatment of obesity.

⚖️ POSITIVE for peptide users 👤 LOW user impact 📜 Status: Failed

State: Washington
Bill: SB 6182
Filed: 2024-01-11
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

SB6182 would have required Washington public employee health plans and Medicaid managed care plans to cover FDA-approved GLP-1 agonists and similar obesity drugs for eligible patients. It does not appear to address compounded peptides, telehealth rules, naturopath or NP scope, 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

Would have expanded coverage for obesity GLP-1 drugs in Medicaid managed care
Would have applied to Washington public employee health plans
Eligibility was tied to obesity or BMI 27+ with a weight-related condition
The bill focused on FDA-approved obesity drugs, not compounded versions
No direct changes to telehealth, prescribing scope, or PDMP rules

What to Watch For

✓

Opportunity Similar future bills could improve insurance access to GLP-1 medications for obesity.

Note Coverage language appears aimed at FDA-approved products, not compounded semaglutide or tirzepatide.

Note Clinicians would still need to follow existing prescribing, prior authorization, and scope rules.

Where the Bill Stands

The bill received a Senate committee hearing in January 2024 but did not advance before the 2023-2024 session ended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-02 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws